4 results match your criteria: "China. gcg2022@hospital.cqmu.edu.cn.[Affiliation]"
BMC Urol
October 2023
Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Background: Existing epidemiological observational studies have suggested interesting but inconsistent clinical correlations between inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), and kidney stone disease (KSD). Herein, we implemented a two-sample bidirectional Mendelian randomization (MR) to investigate the causal relationship between IBD and KSD.
Methods: Data on IBD and KSD were obtained from Genome-Wide Association Studies (GWAS) summary statistics and the FinnGen consortium, respectively.
Investig Clin Urol
May 2023
Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
To systematically evaluate the differences in therapeutic response to chemotherapy or immunotherapy between different molecular subtypes of bladder cancer (BC). A comprehensive literature search was performed up to December 2021. Consensus clusters 1 (CC1), CC2 and CC3 molecular subtypes were used to perform meta-analysis.
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
September 2023
Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, No.76, Linjiang Road, Yuzhong District, Chongqing, 400010, People's Republic of China.
BMC Urol
May 2023
Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong district, Chongqing, 400010, China.
Background: Clear cell renal cell carcinoma (ccRCC) is one of the most common malignancies. Recently, immunotherapy has been considered a promising treatment for metastatic ccRCC. NUF2 is a crucial component of the Ndc80 complex.
View Article and Find Full Text PDF